Fig. 3From: Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyResidual monthly migraine days (A) and Headache Impact Test-6 score (B) at weeks 9-12 according to erenumab response categoriesBack to article page